09:02 : The Funded: NComputing, Corcept Therapeutics -
Here are fundings from Silicon Valley companies, announced or filed recently with the U.S. Securities and Exchange Commission. The Funded is a recurring feature where we post new fundings that cross our desks, as well as an archive of past fundings. ...
17:14 : Corcept Therapeutics (CORT), a specialty drug company that hasn't generate -
Corcept Therapeutics (CORT), a specialty drug company that hasn't generated revenue since 2009, wins FDA approval for its Korlym treatment that uses the active ingredient of the abortion pill RU-486 to treat Cushing's Syndrome. ...
11:13 : Corcept Therapeutics ([[CORT]] -8.7%) sinks on heavy volume, despite regul -
Corcept Therapeutics (CORT -8.7%) sinks on heavy volume, despite regulators accepting its application to market Corlux as a treatment for Cushing's Syndrome. After final approval, Corcept will have seven years to market the ...
12:36 : Corcept Therapeutics Announces Detailed Findings From Phase 3 Study Which ... -
CORLUX Was Well Tolerated and Enabled Almost 50% of Patients Taking Anti-Diabetic, Insulin and Hypertensive Medications at Enrollment to Reduce the Dosage by Study's End Company to Host Conference Call on Sunday, June 5, 2011 at 8 a.m. Eastern Daylight ...